AMAG Pharmaceuticals (NASDAQ:AMAG) dropped slightly amid mild profit booking and the last known price was $23.63 per share. The price decreased by -0.01 points or -0.04% which made the investors to buy on weakness. For the latest trading session, the net money flow was recorded at $3.52 million. The total upticks were valued at $6.82 million and the total downticks aggregated to $3.3 million, thereby putting the up/down ratio at 2.07,. The shares have seen a change in the share price of 1.72% on a weekly basis.In a big block trade which occurred today, the total uptick value was $3.67 million and the total downtick value was $0, resulting in an up/down ratio of 0. The net money flow for the block trade was calculated to be $3.67 million.
The stock has recorded a 20-day Moving Average of 8.65% and the 50-Day Moving Average is 4.5%. The company shares have dropped 67.75% in the past 52 Weeks. On July 17, 2015 The shares registered one year high of $77.73 and one year low was seen on May 19, 2016 at $17.92. The 50-day moving average is $20.87 and the 200 day moving average is recorded at $24.06. S&P 500 has rallied 1.93% during the last 52-weeks.
AMAG Pharmaceuticals (NASDAQ:AMAG): The stock opened at $23.74 on Tuesday but the bulls could not build on the opening and the stock topped out at $23.92 for the day. The stock traded down to $23.08 during the day, due to lack of any buying support eventually closed down at $23.63 with a loss of -0.04% for the day. The stock had closed at $23.64 on the previous day. The total traded volume was 903,320 shares.
Currently the company Insiders own 2.3% of AMAG Pharmaceuticals shares according to the proxy statements. On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Amag Pharmaceuticals Inc., Fallon John A. had purchased shares worth of $100,776 in a transaction dated on November 10, 2015. A total of 3,230 shares were purchased at a price of $31.2 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.